breast%20cancer
BREAST CANCER
Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the breast. The lump or mass is usually painless, hard & irregular but it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple discharge, nipple retraction and presence of breast skin changes (eg peau d' orange, nipple excoriation, scaling, inflammation, skin tethering, ulceration, abscess).

Introduction

  • Refers to both invasive and in situ carcinoma of the breast
  • Most common and frequently diagnosed noncutaneous cancer in women

Signs and Symptoms

  • Presence of breast nodule, mass, or abscess
    • Most common symptom of breast cancer is a new lump or mass in the breast
    • Painless, hard, and irregular mass is more likely to be cancerous, but can also be tender, soft, rounded, or painful
  • Breast pain or nipple pain
  • Nipple discharge
  • Nipple retraction
  • Presence of breast skin changes (eg peau d’ orange, nipple excoriation, scaling, inflammation, skin tethering, ulceration, abscess)

Risk Factors

  • History of breast cancer
    • Previous history of breast cancer has an increased risk of developing new primary breast cancer
      • History of invasive breast cancer, lobular neoplasia [formerly called lobular carcinoma in situ (LCIS)] and ductal carcinoma in situ (DCIS) have the highest risk
    • Breast carcinoma in situ can develop into invasive breast cancer

  • Confirmed biopsy of benign proliferative breast disease
    • Breast tissue biopsy showing proliferative disease with and without atypical cells has an elevated risk of developing breast cancer
      • Patients with benign breast disease that presents with atypical hyperplasia carry the highest risk of developing cancer

  • History of high-dose radiation exposure
    • Multiple exposures of therapeutic radiation to the chest for cancer at an early age (<20 years old) increase the risk of breast cancer
    • Contralateral breast cancer has been shown to develop after high-dose radiation exposure
    • Patients with Hodgkin’s disease receiving radiotherapy at high doses are also at risk

  • Reproductive factors
    • Nulliparity or first full-term pregnancy at age >30 years
      • Breastfeeding for >12 months is protective against breast cancer
    • Menarche at age <12 years and menopause at age >55 years
    • Oral contraceptive use before the first full-term pregnancy, combination hormone replacement therapy, and long-term use of unopposed estrogen for >15 years by hysterectomized women have mild increased risk for breast cancer
      • Use of low-dose preparations poses a lower risk

  • Advanced age
    • Risk increases from 40 years old for premenopausal women and 50 years old for postmenopausal women

  • Family history of breast cancer
    • Increased risk in women with breast cancer among young first-degree relatives
      • Sister has a higher risk than a mother
    • Carriers of BRCA1 and BRCA2 genetic mutations are also at high risk
      • Women with these have increased risk of developing other cancers like ovarian cancer
  • Breast density
    • Higher breast density has increased risk
    • Lifestyle
      • Body mass index of >25 has an increased risk of developing breast cancer with higher death rate
        • 7 hours/week of moderate to vigorous exercise was shown to be inversely related to breast cancer development
      • Alcohol consumption (eg beer) of >10 g/day especially in postmenopausal women has increased risk for invasive breast cancer
    Digital Edition
    Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
    DOWNLOAD
    Editor's Recommendations
    Most Read Articles
    Audrey Abella, 09 Jun 2017
    Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
    Elvira Manzano, 14 Jun 2017
    The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
    Pearl Toh, 01 Aug 2016
    Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
    Audrey Abella, 13 Jun 2017
    A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.